493 related articles for article (PubMed ID: 32051167)
1. Current and future applications of liquid biopsy in nonsmall cell lung cancer from early to advanced stages.
Guibert N; Pradines A; Favre G; Mazieres J
Eur Respir Rev; 2020 Mar; 29(155):. PubMed ID: 32051167
[TBL] [Abstract][Full Text] [Related]
2. Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients.
Sorber L; Zwaenepoel K; Deschoolmeester V; Van Schil PE; Van Meerbeeck J; Lardon F; Rolfo C; Pauwels P
Lung Cancer; 2017 May; 107():100-107. PubMed ID: 27180141
[TBL] [Abstract][Full Text] [Related]
3. Tumor-educated platelet as liquid biopsy in lung cancer patients.
Liu L; Lin F; Ma X; Chen Z; Yu J
Crit Rev Oncol Hematol; 2020 Feb; 146():102863. PubMed ID: 31935617
[TBL] [Abstract][Full Text] [Related]
4. Liquid biopsy and its role in an advanced clinical trial for lung cancer.
Johann DJ; Steliga M; Shin IJ; Yoon D; Arnaoutakis K; Hutchins L; Liu M; Liem J; Walker K; Pereira A; Yang M; Jeffus SK; Peterson E; Xu J
Exp Biol Med (Maywood); 2018 Feb; 243(3):262-271. PubMed ID: 29405770
[TBL] [Abstract][Full Text] [Related]
5. Liquid Biopsy - Possibilities for Monitoring the Therapeutic Response in Non-Small Cell Lung Cancer.
Raycheva GA; Ivanov HY; Grudeva-Popova ZG
Folia Med (Plovdiv); 2021 Dec; 63(6):839-846. PubMed ID: 35851241
[TBL] [Abstract][Full Text] [Related]
6. The Present and Future of Liquid Biopsies in Non-Small Cell Lung Cancer: Combining Four Biosources for Diagnosis, Prognosis, Prediction, and Disease Monitoring.
Bracht JWP; Mayo-de-Las-Casas C; Berenguer J; Karachaliou N; Rosell R
Curr Oncol Rep; 2018 Jul; 20(9):70. PubMed ID: 30030656
[TBL] [Abstract][Full Text] [Related]
7. Liquid biopsy for therapy monitoring in early-stage non-small cell lung cancer.
Nagasaka M; Uddin MH; Al-Hallak MN; Rahman S; Balasubramanian S; Sukari A; Azmi AS
Mol Cancer; 2021 Jun; 20(1):82. PubMed ID: 34074295
[TBL] [Abstract][Full Text] [Related]
8. Possible applications of circulating tumor cells in patients with non small cell lung cancer.
Tartarone A; Rossi E; Lerose R; Mambella G; Calderone G; Zamarchi R; Aieta M
Lung Cancer; 2017 May; 107():59-64. PubMed ID: 27339469
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy in nonsmall-cell lung cancer: current status and future prospects for liquid biopsy.
Brozos-Vázquez EM; Díaz-Peña R; García-González J; León-Mateos L; Mondelo-Macía P; Peña-Chilet M; López-López R
Cancer Immunol Immunother; 2021 May; 70(5):1177-1188. PubMed ID: 33113004
[TBL] [Abstract][Full Text] [Related]
10. Letter to the Editor: "Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy".
Nicolazzo C; Raimondi C; Loreni F; Gazzaniga P; Gradilone A
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28629196
[TBL] [Abstract][Full Text] [Related]
11. Liquid Biopsy: Current Status and Future Perspectives.
Mader S; Pantel K
Oncol Res Treat; 2017; 40(7-8):404-408. PubMed ID: 28693023
[TBL] [Abstract][Full Text] [Related]
12. Reply to the Letter to the Editor by C. Nicolazzo et al.: "Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy".
Alama A; Coco S; Vanni I; Grossi F
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28629197
[TBL] [Abstract][Full Text] [Related]
13. Are liquid biopsies a surrogate for tissue EGFR testing?
Goldman JW; Noor ZS; Remon J; Besse B; Rosenfeld N
Ann Oncol; 2018 Jan; 29(suppl_1):i38-i46. PubMed ID: 29462257
[TBL] [Abstract][Full Text] [Related]
14. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.
Villaflor V; Won B; Nagy R; Banks K; Lanman RB; Talasaz A; Salgia R
Oncotarget; 2016 Oct; 7(41):66880-66891. PubMed ID: 27602770
[TBL] [Abstract][Full Text] [Related]
15. Clinical Utility of Liquid Diagnostic Platforms in Non-Small Cell Lung Cancer.
Levy B; Hu ZI; Cordova KN; Close S; Lee K; Becker D
Oncologist; 2016 Sep; 21(9):1121-30. PubMed ID: 27388233
[TBL] [Abstract][Full Text] [Related]
16. Circulating Biomarkers in Non-Small-Cell Lung Cancer: Current Status and Future Challenges.
Matikas A; Syrigos KN; Agelaki S
Clin Lung Cancer; 2016 Nov; 17(6):507-516. PubMed ID: 27373516
[TBL] [Abstract][Full Text] [Related]
17. Liquid Biopsy Promotes Non-Small Cell Lung Cancer Precision Therapy.
Lu J; Han B
Technol Cancer Res Treat; 2018 Jan; 17():1533033818801809. PubMed ID: 30244652
[TBL] [Abstract][Full Text] [Related]
18. Will liquid biopsies improve outcomes for patients with small-cell lung cancer?
Blackhall F; Frese KK; Simpson K; Kilgour E; Brady G; Dive C
Lancet Oncol; 2018 Sep; 19(9):e470-e481. PubMed ID: 30191851
[TBL] [Abstract][Full Text] [Related]
19. Advances in liquid biopsy-based markers in NSCLC.
Ren XD; Su N; Sun XG; Li WM; Li J; Li BW; Li RX; Lv J; Xu QY; Kong WL; Huang Q
Adv Clin Chem; 2023; 114():109-150. PubMed ID: 37268331
[TBL] [Abstract][Full Text] [Related]
20. Clinical feasibility of NGS liquid biopsy analysis in NSCLC patients.
Papadopoulou E; Tsoulos N; Tsantikidi K; Metaxa-Mariatou V; Stamou PE; Kladi-Skandali A; Kapeni E; Tsaousis G; Pentheroudakis G; Petrakis D; Lampropoulou DI; Aravantinos G; Varthalitis I; Kesisis G; Boukovinas I; Papakotoulas P; Katirtzoglou N; Athanasiadis E; Stavridi F; Christodoulou C; Koumarianou A; Eralp Y; Nasioulas G
PLoS One; 2019; 14(12):e0226853. PubMed ID: 31860648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
